Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Autoimmunity in a genetic disease—a cautionary tale.

Moore MJ, Flotte TR.

N Engl J Med. 2010 Oct 7;363(15):1473-5. doi: 10.1056/NEJMe1009056. No abstract available.

PMID:
20925551
2.

Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy.

Wells DJ, Ferrer A, Wells KE.

Expert Rev Mol Med. 2002 Nov 4;4(23):1-23. Review.

PMID:
14585159
3.

Gene therapy for Duchenne muscular dystrophy: AAV leads the way.

Judge LM, Chamberlain JS.

Acta Myol. 2005 Dec;24(3):184-93. Review.

PMID:
16629052
4.

[Mutation-specific treatments for Duchenne muscular dystrophy].

Matsuo M, Takeshima Y.

Brain Nerve. 2009 Aug;61(8):915-22. Review. Japanese.

PMID:
19697880
5.

Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.

Yokota T, Pistilli E, Duddy W, Nagaraju K.

Expert Opin Biol Ther. 2007 Jun;7(6):831-42. Review.

PMID:
17555369
6.

[Frontline studies on Duchenne muscular dystrophy treatment].

Matsuo M.

No To Hattatsu. 2009 Mar;41(2):92-5. Review. Japanese.

PMID:
19517771
7.

Exon-skipping therapy for Duchenne muscular dystrophy.

Nakamura A, Takeda S.

Neuropathology. 2009 Aug;29(4):494-501. doi: 10.1111/j.1440-1789.2009.01028.x. Epub 2009 May 22. Review.

PMID:
19486303
8.

Retroviral vectors for gene therapy of Duchenne muscular dystrophy.

Fassati A, Bresolin N.

Neurol Sci. 2000;21(5 Suppl):S925-7. Review.

PMID:
11382191
9.

Therapeutic strategies for Duchenne and Becker dystrophies.

Voisin V, de la Porte S.

Int Rev Cytol. 2004;240:1-30. Review.

PMID:
15548414
10.

Gene therapy for duchenne muscular dystrophy: expectations and challenges.

Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR.

Arch Neurol. 2007 Sep;64(9):1236-41. Review.

PMID:
17846262
11.

Duchenne muscular dystrophy: current knowledge, treatment, and future prospects.

Biggar WD, Klamut HJ, Demacio PC, Stevens DJ, Ray PN.

Clin Orthop Relat Res. 2002 Aug;(401):88-106. Review.

PMID:
12151886
12.

Gene therapy progress and prospects: Duchenne muscular dystrophy.

Foster K, Foster H, Dickson JG.

Gene Ther. 2006 Dec;13(24):1677-85. Epub 2006 Oct 26. Review.

PMID:
17066097
13.

[Future treatment modalities in Duchenne muscular dystrophy].

Oron A, Shuper A, Shohat M.

Harefuah. 1998 Apr 1;134(7):557-60. Review. Hebrew. No abstract available.

PMID:
10909603
14.

The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.

Roberts M, Dickson G.

Curr Opin Mol Ther. 2002 Aug;4(4):343-8. Review.

PMID:
12222872
15.

Non-viral approaches for gene transfer.

Wolff J, Lewis DL, Herweijer H, Hegge J, Hagstrom J.

Acta Myol. 2005 Dec;24(3):202-8. Review.

PMID:
16629054
16.

Immunobiology and the future of myoblast transfer therapy.

Smythe GM, Hodgetts SI, Grounds MD.

Mol Ther. 2000 Apr;1(4):304-13. Review.

17.

Splicing intervention for Duchenne muscular dystrophy.

McClorey G, Fletcher S, Wilton S.

Curr Opin Pharmacol. 2005 Oct;5(5):529-34. Review.

PMID:
16085461
18.

Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.

Wilton SD, Fletcher S.

Acta Myol. 2005 Dec;24(3):222-9. Review.

PMID:
16629057
19.

[Gene therapy for muscular dystrophy].

Takeda S.

No To Hattatsu. 2004 Mar;36(2):117-23. Review. Japanese.

PMID:
15031985
20.

Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy.

Alman BA.

J Pediatr Orthop. 2005 Jul-Aug;25(4):554-6. Review. No abstract available.

PMID:
15958914
Items per page

Supplemental Content

Write to the Help Desk